ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics, Inc. (Nasdaq: ZEVRA) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing life-changing therapies for patients with rare diseases. The company operates through a portfolio of approved products and clinical-stage candidates addressing ultra-rare genetic and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ZEVRA THERAPEUTICS, INC. does
In the company’s own words
Zevra Therapeutics, Inc. (Nasdaq: ZEVRA) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing life-changing therapies for patients with rare diseases. The company operates through a portfolio of approved products and clinical-stage candidates addressing ultra-rare genetic and neurological disorders where treatment options are limited or nonexistent.
Zevra's lead commercial product is MIPLYFFA (arimoclomol), approved by the FDA in September 2024 for the treatment of neurological manifestations of Niemann-Pick disease type C in combination with miglustat. MIPLYFFA represents the first FDA-approved therapy for this ultra-rare, progressive neurodegenerative disease affecting approximately 900 patients in the United States. The company also markets OLPRUVA (sodium phenylbutyrate) for oral suspension, approved for the chronic management of urea cycle disorders in the United States, though the company is currently evaluating strategic alternatives for this product.
The company's clinical pipeline includes celiprolol, a selective adrenoceptor modulator in Phase 3 development for Vascular Ehlers-Danlos Syndrome, and KP1077, a proprietary formulation containing serdexmethylphenidate in development for idiopathic hypersomnia and narcolepsy. Additionally, Zevra receives royalties and milestone payments on AZSTARYS, an FDA-approved ADHD treatment developed using the company's proprietary Ligand Activated Technology platform and commercialized through a partnership with Commave.
Zevra's portfolio was assembled through strategic acquisitions, including the May 2022 purchase of Orphazyme's arimoclomol assets and the November 2023 acquisition of Acer Therapeutics, which brought OLPRUVA and celiprolol into the company's pipeline. The company has built commercial infrastructure including specialized sales teams, patient reimbursement services, medical affairs, and market access capabilities to support its rare disease focus. Zevra maintains a global presence with development and commercialization activities spanning the United States and Europe. The company's intellectual property portfolio includes approximately 87 active U.S. patents and 497 active foreign patents protecting its selected prodrugs and product candidates, with patent protection extending through 2044 for certain assets.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1434647
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ZEVRA THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ZEVRA THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ZEVRA THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ZEVRA THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ZEVRA THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”